DE-BIOCORP
19.2.2020 18:02:08 CET | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization.
In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management.
This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration").
Ryan Sysko, President and CEO of Amalgam Rx, Inc, said: "We are very pleased with this partnership to interface Mallya with our iSage app. Combining these two solutions offers to date the most powerful environment for diabetes digitalization and patient support. Together, we can simplify the often complex and confusing journey for patients starting on basal insulin. “
Éric Dessertenne, CEO of BIOCORP, concluded: "For patients with diabetes, the integration of Mallya and iSage provides an additional brick of information to improve their quality of life. For the community of diabetes, this integration is a powerful service platform that takes into account all the clinical and behavioral needs of patients. "
ABOUT ISAGE RX
iSage Rx, manufacturers of the iSage App, the first FDA 510(k)-cleared, prescription-only mobile application for the automated titration of all brands of basal insulin. iSage allows physicians to choose from multiple clinically-validated basal insulin algorithms and tailor the algorithms to the specific needs of their type 2 diabetes patients. iSage Rx is a wholly-owned subsidiary of Amalgam Rx. For more information, visit http://isageapp.com .
ABOUT AMALGAM RX
Amalgam Rx creates custom digital therapies that combine clinical and behavioral health and interventions to engage, support, and improve patient self-management. Led by an experienced team of physicians, behaviorists, technologists, and digital health pioneers, Amalgam Rx strives to use technology to accelerate the impact and scale of medicine to improve the lives of millions of people living with chronic disease. Amalgam does this by partnering with leading life sciences companies to accelerate the R&D and commercialization of digital therapeutics. For more information, visit http://amalgamrx.com/ .
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
Follow us on Twitter @BIOCORPSystems
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005728/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CapVest Completes Majority Acquisition of Stada31.3.2026 13:10:00 CEST | Press release
CapVest Partners LLP (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty Pharmaceuticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331987319/en/ Building on strong 2025 results, the completion of the transaction will allow the CapVest and STADA teams to jointly progress their ambitious plans to accelerate the growth of the company globally and deploying capital towards pursuing organic growth and new strategic acquisitions. Currently employing close to 12,000 people worldwide, STADA is a leading, diversified global healthcare platform with a strategic focus on Consumer Healthcare, Generics and Specialty Pharmaceuticals. The Company recently announced record revenues of €4.3 billion, a 6% incr
GetVocal Introduces Control Center to Help Enterprises Scale AI Across 90 Percent Plus of Customer Conversations31.3.2026 13:00:00 CEST | Press release
New governance layer enables human-in-the-loop operations, allowing AI to handle customer interactions while humans stay in control of critical decisions GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the launch of its Control Center, a human-AI operations interface designed to help enterprises scale customer experience (CX) automation while maintaining trust, compliance, and full human oversight. As organizations expand AI from simple requests to complex customer journeys, they face a dual operational challenge: if AI acts alone, risk increases; but if humans review everything, automation doesn’t scale. GetVocal’s Control Center solves this challenge by introducing a governance layer for real-time two-way human-AI collaboration. In this hybrid workforce model, AI resolves most customer interactions independently, and humans step in only when judgment, validation, or exception handling is required. The Control Center is
Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code31.3.2026 13:00:00 CEST | Press release
New AI-platform enables non-tech teams to build fully functional, secure applications for real business operations, not just prototypes Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need. This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay. Softr’s new platform was built to brid
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform31.3.2026 12:00:00 CEST | Press release
Round Led by Collaborative Fund with Participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Cristiano Ronaldo, LeBron James, Rory McIlroy WHOOP, the human performance company, today announced it has raised $575 million in Series G funding at a $10.1 billion valuation, advancing its global expansion and long-term vision for personalized health. The round was led by Collaborative Fund and includes global participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Macquarie Capital (entities administered by Macquarie Capital), Glade Brook, B-Flexion, IVP, Foundry, Accomplice, Affinity Partners, Promus Ventures, and Bullhound Capital alongside a group of prominent global athletes and individual investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331399622/en/ WHOOP Raises $575 Million at $10.1 B
Interactive Brokers Launches Crypto-Asset Trading for Individual Investors in the European Economic Area31.3.2026 11:00:00 CEST | Press release
Eligible clients can now trade 11 popular crypto-assets including Bitcoin and Ethereum alongside stocks, options, futures, and more, all from a single, integrated platform Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of crypto-asset trading for eligible individual investors in the EEA through Interactive Brokers Ireland Limited, which is an authorised crypto-asset service provider in the EEA. Many European investors face challenges managing multiple crypto apps, understanding unclear fees, or navigating security concerns. Interactive Brokers now offers a solution. Starting today, eligible individual investors in the EEA can trade 11 leading crypto-assets directly on the same platform they already use for stocks, options, futures, currencies, bonds, and mutual funds. This integrated approach gives clients a unified view of their entire portfolio. With one login, they can manage both traditional and crypto-assets, backed by the control, low p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom